N	Concordance
1	the efficacy of ribavirin and IFN-alpha combination therapy for IFN-alpha resist
2	 potential use of natural product-based combination therapy for treating prostat
3	ith breast cancer received adjuvant CNF combination therapy (cyclophosphamide, m
4	ng-term treatment. Low-dose, fixed-dose combination therapy may therefore repres
5	my associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 
6	ase of advanced breast cancer receiving combination therapy with 5'-DFUR and MPA
7	icantly higher for interferon-ribavirin combination therapy than for interferon 
8	jection fraction. In summary, long-term combination therapy of ACE inhibitors an
9	s comparing zidovudine monotherapy with combination therapy have now clearly est